iRhythm Q2 FY26: revenue +20%, operating loss narrows 86%, $95M in litigation settlements

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Jul 31, 2025 · ~2 min read

Key Changes

• high

  Subsequent event: On July 31, 2026, iRhythm Technologies entered into the Baxter Settlement Agreement with the Baxter Parties to resolve all outstanding patent litigation among the parties. Under the Baxter Settlement Agreement, the Co…

  Notes: Subsequent Events verify on EDGAR →
• high

  Revenue grew 20.1% YoY to $224.2M in Q2 FY26, driven by volume growth across Zio monitor and Zio AT in all customer groups, improved contractual allowance reserves, and annual CMS reimbursement increases.

  MD&A: Revenue Growth verify on EDGAR →
• high

  Operating loss narrowed 86% YoY from $18.7M to $2.5M in Q2 FY26, reflecting strong revenue growth, improved gross margins from manufacturing efficiencies, and operating leverage despite a $14M net litigation settlement expense.

  MD&A: Operating Loss verify on EDGAR →